Published in Cancer on December 15, 2009
Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20
Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst (2014) 1.28
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br J Cancer (2010) 1.24
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene (2013) 1.23
Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut (2010) 1.20
Common colorectal cancer risk variants in SMAD7 are associated with survival among prediagnostic nonsteroidal anti-inflammatory drug users: a population-based study of postmenopausal women. Genes Chromosomes Cancer (2011) 0.99
Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer (2012) 0.98
Pre-diagnostic NSAID use but not hormone therapy is associated with improved colorectal cancer survival in women. Br J Cancer (2011) 0.98
Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol (2011) 0.96
Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo. Br J Pharmacol (2012) 0.91
Role of vitamin and mineral supplementation and aspirin use in cancer survivors. J Clin Oncol (2010) 0.89
PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study. PPAR Res (2010) 0.88
The association between NSAID use and colorectal cancer mortality: results from the women's health initiative. Cancer Epidemiol Biomarkers Prev (2012) 0.86
Meat consumption, nonsteroidal anti-inflammatory drug use, and mortality among colorectal cancer patients in the California Teachers Study. Cancer Prev Res (Phila) (2010) 0.83
Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer (2013) 0.82
Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011. Ecancermedicalscience (2012) 0.77
Influence of NSAID Use Among Colorectal Cancer Survivors on Cancer Outcomes. Am J Clin Oncol (2014) 0.77
Prediagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients. Therap Adv Gastroenterol (2016) 0.76
Clinical trials update: Tertiary prevention of colorectal cancer. J Carcinog (2011) 0.75
Meat consumption, ornithine decarboxylase gene polymorphism, and outcomes after colorectal cancer diagnosis. J Carcinog (2012) 0.75
Aspirin, salicylates and cancer: report of a meeting at the Royal Society of Medicine, London, 23 November 2010. Ecancermedicalscience (2011) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med (2003) 6.99
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13
A prospective study of family history and the risk of colorectal cancer. N Engl J Med (1994) 6.12
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med (1994) 5.42
A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol (2001) 4.61
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control (2002) 3.81
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med (2007) 3.64
A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med (2004) 3.46
COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol (2005) 3.15
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst (2007) 2.95
Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg (1993) 2.70
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA (2008) 2.67
Colon cancer: a review of the epidemiology. Epidemiol Rev (1993) 2.65
Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology (1991) 2.43
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res (1996) 2.27
Family history of cancer and colon cancer risk: the Utah Population Database. J Natl Cancer Inst (1994) 2.14
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol (2001) 1.98
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res (2000) 1.96
Recent diet and breast cancer risk: the California Teachers Study (USA). Cancer Causes Control (2002) 1.70
Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res (1987) 1.23
Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen (2004) 1.23
Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev (2006) 1.20
Survival after colorectal cancer diagnosis is associated with colorectal cancer family history. Cancer Epidemiol Biomarkers Prev (2008) 1.18
Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology (1998) 1.16
Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int J Cancer (2007) 1.12
A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res (2003) 1.05
Family history and survival after colorectal cancer diagnosis. Cancer (2008) 1.04
Clinical and pathological analyses of patients with a family history of colorectal cancer. Registry Committee, Japanese Research Society for Cancer of the Colon and Rectum. Jpn J Clin Oncol (1993) 1.01
The effect of family history of cancer, religion, parity and migrant status on survival in colorectal cancer. The Melbourne Colorectal Cancer Study. Eur J Cancer (1992) 1.00
The impact of family history of colon cancer on survival after diagnosis with colon cancer. Int J Epidemiol (1995) 1.00
Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer (2002) 0.98
Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum (2004) 0.96
Celecoxib with chemotherapy in colorectal cancer. Oncology (Williston Park) (2002) 0.91
Chemoprevention of colorectal cancer. Dis Colon Rectum (2006) 0.86
Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice. Int J Cancer (2005) 0.84
A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer. Prostaglandins Other Lipid Mediat (2005) 0.78
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Body-mass index and mortality among 1.46 million white adults. N Engl J Med (2010) 13.34
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med (2006) 7.82
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
A common genetic risk factor for colorectal and prostate cancer. Nat Genet (2007) 7.11
Multiple common variants for celiac disease influencing immune gene expression. Nat Genet (2010) 6.90
Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect (2004) 6.43
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin (2007) 5.67
Exploiting gene-environment interaction to detect genetic associations. Hum Hered (2007) 5.63
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Effect of population-based screening on breast cancer mortality. Lancet (2011) 5.06
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Oral contraceptives and the risk of breast cancer. N Engl J Med (2002) 4.85
Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg (2015) 4.78
Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet (2006) 4.78
Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control (2008) 4.56
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res (2004) 4.54
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Increasing burden of melanoma in the United States. J Invest Dermatol (2009) 4.43
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA (2005) 3.99
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst (2003) 3.83
High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control (2002) 3.81
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer (2013) 3.75
Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol (2005) 3.65
Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. Am J Epidemiol (2010) 3.64
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res (2006) 3.62
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol (2009) 3.58
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Optimal two-stage genotyping designs for genome-wide association scans. Genet Epidemiol (2006) 3.41
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
Consistent association of type 2 diabetes risk variants found in europeans in diverse racial and ethnic groups. PLoS Genet (2010) 3.27
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer (2003) 3.25
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Lung cancer incidence in never smokers. J Clin Oncol (2007) 3.20
Clinically relevant changes in family history of cancer over time. JAMA (2011) 3.18
Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev (2003) 3.11
Influence of individual and combined health behaviors on total and cause-specific mortality in men and women: the United Kingdom health and lifestyle survey. Arch Intern Med (2010) 3.08
A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res (2007) 3.08
The landscape of recombination in African Americans. Nature (2011) 3.06
Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res (2006) 3.06
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Physical activity levels among breast cancer survivors. Med Sci Sports Exerc (2004) 2.88
Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol (2008) 2.85
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Validation of family history data in cancer family registries. Am J Prev Med (2003) 2.80
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78